Effect of Pioglitazone therapy on Early Non Proliferative Diabetic Retinopathy

Authors
Swati Agarwal¹, Shikha Agarwal²*, Sanjiv Gupta³, Navendu Rai⁴

¹Consultant Eye Surgeon, Lucknow Eye Hospital, Lucknow
²Assistant Professor, Ophthalmology, Mayo Institute Of Medical Sciences, Barabanki,
³Professor, Department of Ophthalmology, king George Medical University, Lucknow
⁴Consultant Eye Surgeon, Dr. navendu eye care centre, Deoria, India

Name and address of Institute where study had been done: Lucknow Eye Hospital, Lucknow, India

*Corresponding Author
Dr Shikha Agarwal
10/403, Malhar Deluxe, Sahara Grace Apartment, Jankipuram, Lucknow, Uttar Pradesh, India, 226021

Abstract

Background: Thiazolidinediones are oral hypoglycemic drugs that have been recently used for patients of Type 2 diabetes. Their side effect of systemic fluid retention aggravates diabetic macular edema. This research work was designed to study the change in macular thickness in diabetic patients are Pioglitazone.

Method: A prospective study was undertaken. Metabolically stable Type 2 diabetes were taken up for study and followed for three months who fulfilled the inclusion criteria. Group I included patients with no diabetic retinopathy. Group II included patient with mild / moderate retinopathy without macular edema. Two groups were further randomized into subgroups ‘A’ & ‘B’. ‘A’ received standard systemic medical therapy for diabetes and second subgroup received 30mg pioglitazone in addition to standard treatment. Spectral domain Optical Coherence Tomography was used to measure central foveal thickness at baseline, 6 weeks and 12 weeks.

Result: 66 cases were included. The increase in central foveal thickness (baseline-1200) in groups on pioglitazone (18-9.00±5.41µ, 2B-9.29±3.18µ) was statistically higher than without pioglitazone (1A-0.39±2.86µ, 2A-1.56±4.27µ) (P<0.001).

Conclusion: Pioglitazone therapy is related to statistically significant increase in macular thickness at three month follow up. Optical Coherence Tomography (OCT) is an important tool for picking up subclinical changes in macular thickness that do not reflect in visual acuity.

Keywords: Non proliferative diabetic retinopathy, Diabetic retinopathy, Pioglitazone, Macular thickness.

Background
At least 171 million people worldwide suffer from diabetes and this is estimated to be doubled by 2030 (WHO²). Most common cause visual impairment in diabetic retinopathy (DR) is because of macular edema.

Optical Coherence Tomography (OCT) is a new investigative tool for quantification and
classifying macular edema.\textsuperscript{2,3} By measuring thickness it aids in early detection of macular edema and also in serial follow ups of patients on treatment. The mean macular thickness is large in all regions for eyes with Non proliferative diabetic retinopathy (NPDR) or proliferative Diabetic Retinopathy (PDR) compared with the normal eyes. This difference is most significant in average and central foveal thickness.\textsuperscript{4} The therapy for diabetes mellitus (DM) mainly includes Diet, exercise, life style and pharmacological management. Rosiglitazone and Piogliazone have been evaluated in clinical trial in patients of type -2 (DM). Both these drugs have a beneficiary role in diabetic retinopathy (DR) (by reducing hyperglycemia it tends to lower the progression of DR) is in contradiction to what its side effect of systemic fluid retention may have [systemic fluid retention can aggravate diabetic macular edema (DME)]. Review of literature provided instances of aggravation of DME attributed to use of this class of medicine.\textsuperscript{5,6,7,8,9,10}.

**Method**

A prospective study was conducted between November 2017 to march 19 on 122 consecutive eyes of 66 patients to access the effect of pioglitazone therapy on early NPDR. Aim of study was to look for change in macular thickness in diabetic patients on Pioglitazone. Diabetic patients who fulfilled the inclusion & exclusion criteria were enrolled. Exclusion criteria was patients with Type 2 DM without DR or with mild / moderate NPDR without DME and those who completed their 3 months follow up. Exclusion Criteria were:- (1) Patients receiving glitazones before enrolment into the study. (2) Any Intraocular surgery or recent pseudophakia (<3 months). (3) Any ocular disease (except early cataract). (4) Hazy ocular media that occluded Fundus imaging. (5) Hypertension with poor control,(6) Hypoproteinemia. (7) Patient on any drugs known to cause macular edema – Meglitinides, Niacin, Echothiophate iodide, Zidavodine, Leflunomide, Tamoxifen and diuretic drugs Pedal edema at the time of presentation. (8) Any debilitating systemic illness. (9) Any history of coronary artery disease, Renal disease (Serum Creatinine > 1.6mg/dl 24 hours urinary protein > 500 mg) and congestive heart failure. Patients were enrolled after giving a written consent and divided into two groups based on Early Treatment Diabetic Retinopathy Study (EDTRS)\textsuperscript{10} classification. Group one included patients of type 2 DM with no DR, Group two included patients of Type 2 DM with mild/ moderate NPDR without macular edema. The two groups were further randomized into two subgroups. First subgroup (Subgroup A) received the standard systemic medical therapy for diabetes. The second subgroup (Subgroup B) received 30mg of pioglitazone in addition to standard treatment. A detailed history of all patients was taken. Ocular examination included Best Corrected Visual Activity (BCVA) on ETDRS Chart. Anterior segment examination by Slit lamp biomicroscope and applanation tonometry was done. Fundus examination by 90 D lens and central 50º fundus photograph were taken. Fundus Fluorescein Angiography (FFA) was done if required. Macular thickness was studied by OCT using Cirrus HD – OCT (Carl Zeiss Meditee, Dubling CA) scanning protocol was 512 x 128 combo, and the retinal thickness was measured in microns (\(\mu\)). Retinal maps were analysed for all patients and average cube thickness and central foveal retinal thickness was measured. Weight was measured. Patients were examined for pedal edema, facial puffiness and chest crepitation. All patients were subjected to following baseline investigations:- Blood Pressure recording, Blood glycosylated Haemoglobin, Blood Haemoglobin level, Blood Urea, Serum Creatinine and Protein level. Fasting Lipid Profile, 24 hours urinary protein and ECG. All subjects were followed up at 6 and 12 weeks of therapy. All subjects underwent complete ocular & systemic examination including OCT on both visits.
The statistical analysis was done using Statistical Package for Social Sciences (SPSS) version 150 statistical Analysis Software.

Result
There were total of 66 patients (29 females and 37 males) with a mean age of 55.98± 7.88 years. Group wise distribution of all patients is given in Table 1.
The four groups did not differ significantly in all of the biochemical parameters, weight and both systolic and diastolic blood pressure at base line. In measuring retinal thickness of macula, at baseline average cube thickness ranged from 260.78±15.29 to 2667.39±8.30μm. At 6 week interval the average cube thickness in different groups ranged from 260.70±15.70 to 267.55±8.74. At 3 months the average cube thickness ranged from 261.33±14.94 to 269.96±10.47. At 3 months there was a statistical significant difference among the groups. At 6 weeks, maximum change in foveal thickness was seen in group IB (Table 2 ). At baseline mean central foveal thickness of macula was found to be maximum in Group IIB (254.83±22.57) while the minimum was observed in Group IA (235.92±18.22) showing a statistically difference among the groups (P=0.0008) at 6 weeks and 3 months too, the trend did not change.(Table -3)
At baseline the central foveal thickness in NPDR group was significantly higher as compared to No DR group (p=0.001), however, there was no significant difference in change in central thickness in two groups at the end of 3 months (p=0.430) (Table -4).
Mean change in visual activity were not found to be significant statistically in different groups between baseline to 6 weeks and baseline to 3 months. (as shown in Table-5).

Table 1: Group wise distribution of all patients

| Group   | Group IA | Group IB | Group IIA | Group IIB |
|---------|----------|----------|-----------|-----------|
| No. of Subjects | 19       | 18       | 15        | 14        |
| No. of Eyes     | 38       | 33       | 27        | 24        |

Table 2: Change in average cube thickness in different groups at different time intervals

| SN | Group   | Baseline vs 6 weeks | Baseline Vs 3 months | 6 weeks vs 3 months |
|----|---------|---------------------|----------------------|--------------------|
|    | Mean    | SD                  | “t”                  | “p”                | Mean    | SD                  | “t”                  | “p”                |
| 1. | IA      | 0.18                | 1.23                 | 0.361              | 0.68     | 2.16                | 1.955                | 0.058              |
|    | (n=38)  | 0.02                | 0.11                 | 0.061              | 0.50     | 1.67                | 1.843                | 0.073              |
| 2. | IB      | 1.70                | 3.10                 | 3.147              | 4.39     | 3.18                | 7.934                | <0.001             |
|    | (n=33)  | 1.47                | 1.22                 | 1.346              | 0.56     | 2.41                | 1.199                | 0.241              |
| 3. | IIA     | 0.07                | 1.33                 | 0.290              | 0.56     | 2.41                | 1.199                | 0.241              |
|    | (n=27)  | 0.02                | 0.11                 | 0.061              | 0.50     | 1.67                | 1.843                | 0.073              |
| 4. | IIB     | 0.92                | 2.36                 | 1.905              | 4.33     | 1.58                | 13.446               | <0.001             |
|    | (n=24)  | 0.47                | 1.81                 | 1.612              | 0.32     | 2.86                | 0.681                | 0.500              |
|    |         | 0.11                | 0.11                 | 0.061              | 0.50     | 1.67                | 1.843                | 0.073              |
| 5. | IA      | 3.06                | 4.96                 | 3.548              | 9.00     | 5.41                | 9.549                | <0.001             |
|    | (n=33)  | 2.87                | 4.38                 | 3.516              | 0.41     | 3.57                | 0.594                | 0.558              |
| 6. | IIB     | 4.35                | 3.376                | 0.003              | 9.29     | 3.18                | 14.303               | <0.001             |
|    | (n=24)  | 4.35                | 3.376                | 0.003              | 9.29     | 3.18                | 14.303               | <0.001             |

Table 3: Mean Change in Central Foveal Thickness in different groups at different time intervals

| SN | Group   | Baseline vs 6 weeks | Baseline Vs 3 months | 6 weeks vs 3 months |
|----|---------|---------------------|----------------------|--------------------|
|    | Mean    | SD                  | “t”                  | “p”                | Mean    | SD                  | “t”                  | “p”                |
| 1. | IA      | 0.47                | 1.81                 | 1.612              | 0.32     | 2.86                | 0.681                | 0.500              |
|    | (n=38)  | 0.11                | 0.11                 | 0.061              | 0.50     | 1.67                | 1.843                | 0.073              |
| 2. | IB      | 3.06                | 4.96                 | 3.548              | 9.00     | 5.41                | 9.549                | <0.001             |
|    | (n=33)  | 3.05                | 4.38                 | 3.516              | 0.41     | 3.57                | 0.594                | 0.558              |
| 3. | IIA     | 0.41                | 3.57                 | 0.594              | 1.56     | 4.27                | 1.892                | 0.070              |
|    | (n=27)  | 0.41                | 3.57                 | 0.594              | 1.56     | 4.27                | 1.892                | 0.070              |
| 4. | IIB     | 3.00                | 4.35                 | 3.376              | 9.29     | 3.18                | 14.303               | <0.001             |
|    | (n=24)  | 3.00                | 4.35                 | 3.376              | 9.29     | 3.18                | 14.303               | <0.001             |
Table 4: Comparison of Central Thickness in NPDR and No DR Groups

| S.No. | Variable                        | No DR (n=71) | NPDR (n=51) | “t”  | “p”   |
|-------|---------------------------------|--------------|-------------|------|-------|
|       | Mean               | SD           | Mean               | SD           |       |       |
| 1     | Central thickness at baseline  | 237.35       | 18.50       | 250.98  | 27.41  | 3.279 | 0.001 |
| 2     | Changes in central thickness  | 4.35         | 6.06        | 4.35    | 6.06   | 0.792 | 0.430 |

Table 5: Mean Visual Acuity in different groups at different time intervals

| SN | Group     | At Baseline | At 6 wks | At 3 months |
|----|-----------|-------------|----------|-------------|
|    |           | Mean        | SD       | Min | Max | Mean | SD   | Min | Max | Mean | SD   | Min | Max |
| 1. | IA (n=38) | 0.15        | 0.13     | 0   | 0.4 | 0.15 | 0.13 | 0   | 0.4 | 0.17 | 0.12 | 0   | 0.4 |
| 2. | IB (n=33) | 0.13        | 0.13     | 0   | 0.4 | 0.13 | 0.13 | 0   | 0.4 | 0.13 | 0.13 | 0   | 0.4 |
| 3. | IIA (n=27)| 0.19        | 0.18     | 0   | 0.6 | 0.19 | 0.17 | 0   | 0.6 | 0.18 | 0.17 | 0   | 0.6 |
| 4. | IIB (n=24)| 0.13        | 0.13     | 0   | 0.6 | 0.13 | 0.13 | 0   | 0.6 | 0.13 | 0.13 | 0   | 0.6 |

ANOVA 1.233 1.343
“F” 0.301 0.264

Conclusion
This study was aimed at evaluating pioglitazone as a risk factor for increase in macular thickness on OCT. It comprised of four groups (two experimental and two central groups) which were matched for age and sex. They were also comparable for biochemical parameters and duration of diabetes. All the four groups were matched for most of the confounding factors that could independently affect macular edema.

OCT is a new investigative tool for in vivo imaging of the human retina which gives cross sectional information concerning retinal topography and tissue structure with a longitudinal resolution of less than 10 microns and is used clinically for quantification and classification of macular edema. None of the previous studies (except few case reports) used OCT for measuring macular thickness. In this study Spectral domain OCT was used to record baseline average cube thickness and central retinal thickness. Similar measurements were repeated at six weeks follow up and three months follow up for all subjects.

In the macular thickness assessment, central foveal thickness is found to be the most important parameter because of its higher reproducibility and correlation with other measurements of the central macula. Also it is more directly related to the visual acuity, fovea having the most densely clustered cones. Next in line is the average macular thickness.

In this study there was a statistically significant increase in central foveal thickness and average cube thickness in both the groups on Pioglitazone 30mg (Groups IB and IIB). Group IB showed statistically significant difference even at 6 weeks of starting Pioglitazone. The increase in macular thickness detected in our study by OCT was subclinical which could be observed only on very sensitive tool like OCT.

Some of the previous studies have also reported that the use of pioglitazone induced fluid retention with worsening of Diabetic Macular edema and its spontaneous improvement on withdrawal of this group of drugs. There was some contradiction in the scientific literature. In a large multicentre study (ACCORD) no association was observed between use of pioglitazone & DME in type 2 DM in this study.

Our study also had its limitations. Most important being small number of patient short follow up period of three months to study the full effect of the drug. Secondly we did not take subjects with advanced DR or those with macula edema who may have different response as compared to the selected population.
On the basis of our observation and analysis, we came to following conclusions: Pioglitazone therapy is related to a statistically significant increase in macular thickness at three months of follow up, although this increase is subclinical in terms of visual acuity. The average cube thickness & central foveal thickness was found to be significantly higher in the early non proliferative diabetic retinopathy group at baseline, implying that the ongoing diabetic retinopathy has an effect on retinal thickness. OCT is an important tool in direct visualization of retina and picking up subclinical changes in macular thickness that do not reflect in visual acuity. Although the number of patients and length of follow-up in this preliminary study were limited, it has demonstrated a significantly greater risk of developing increased macular thickness in patients of type 2 diabetes mellitus on Pioglitazone therapy, with and without early diabetic retinopathy. So, patients on Pioglitazone therapy must be under regular supervision of an ophthalmologist to observe changes in macular thickness (macular edema).

Sources of support in the form of grants: Nil

References

1. King H et al. Global burden of diabetes. 1995-2025; prevalence numerical estimates and projections. Diabetes care 1998;21:1414-31.
2. Otani T, Kishi S. Patterns of diabetic macular edema with Oct. Am J Ophthalmol 1999;127:688-674.
3. Lattanzio R, Braneto R. Macular thickness measured by OCT in diabetic patients. Eur J Ophthalmol 2002;12: 1482-1496.
4. Hee MR, Carmen A, Jay S. Topography of diabetic macular edema with Oct. Ophthalmol 1998;105:360-370.
5. Colucciello M. Vision loss due to macular edema induce by Rosiglitazone treatment of diabetes mellitus. Arch Ophthalmology 2005;123: 1273-1275.
6. Edwin H. Ryan JR, Dennis P Han, Robert C. Ramsay et al. Diabetic Macular Edema associated with Glitazone use. Retina 2006; 26: 562-570.
7. Liazos E, Broadbent DM, Beare N. Kumar N. Spontaneous resolution of diabetic macular edema after discontinuation of thiazolidinediones. Diabet Med. 2008; 25(7): 860-862.
8. Oshitari T, Asaumi N, Watanabe N, Kumagai K, MItamura Y, Severe macular edema induced by Pioglitazone in a patient with diabetic retinopathy: a case study; Vasc Health Risk Manag. 2008 October; 4(5): 1137-1140.
9. Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D. Retrospective analysis of rosiglitazone and macular oedema in patient type 2 diabetes mellitus. Clin Drug Investig 2008;28(5): 327-32.
10. Fong D S, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009 Apr; 147(4):583-586.el. Epub 2009 Feb1.
11. Browning D J; Optical Coherence Tomography Measurements and Analysis Methods in Optical Coherence Tomography Studies of Diabetic Macular Edema; Ophthalmology. 2008 August; 115(8): 1366-1371.el.
12. Ambrosius WT, Danis RP, Goff DC Jr, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY; ACCORD Study Group. Arch Ophthalmol. 2010 Mar;128(3):312-318.